Evidence · Randomised trial
Inhaled PGE1 in neonates with hypoxemic respiratory failure: two pilot feasibility randomized clinical trials.
- Cardiovascular
- Mechanical ventilation
- Medical
- Persistent pulmonary hypertension
- Respiratory
This paper is from 2014, more than five years ago. Newer evidence may have been published since.
Summary
Report of two multicentre phase II pilot randomised trials assessing the feasibility of inhaled prostaglandin E1 as a selective pulmonary vasodilator in late preterm and term neonates with hypoxaemic respiratory failure. The first pilot enrolled no infants and the second enrolled seven before being halted for recruitment futility. No serious adverse events were reported. The authors discuss the challenges of conducting complex management trials of novel therapies for persistent pulmonary hypertension of the newborn and suggest novel study designs may be needed.
Summary written for NICUlearn. Always read the original.
- Licence:
- Open (Creative Commons)
The full text of this openly licensed paper is available to NICUlearn members, and Neeky can answer questions from it.
Guidelines are shown for education. Follow your unit's own guidance and senior advice.